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Abstract 
Master thesis, Programme in Medicine, 2017 
Soza Zangana 
Department of Clinical Chemistry and Transfusion medicine, Institute of biomedicine, 
Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden 
Critical evaluation of patients sent home from the emergency department with elevated 
troponin T levels 
Background 
The diagnostics of acute myocardial infarction (AMI) is often based on symptoms such as chest 
pain and dyspnea in combination with an electrocardiogram (ECG) and blood samples. When 
the ECG is inconclusive, the diagnostics of AMI is often dependent on significant short time 
change in levels of high sensitive cardiac troponin T (hs-cTnT), indicating acute myocardial 
injury. But, if the event of the AMI occurred a few days before attendance to the emergency 
department (ED), the short time dynamic often required for the diagnosis would not be present, 
and the patient would have a stable troponin elevation above the cut off limit 14 ng/L. The 
hypothesis in this trial is that a follow up sample at least 10 days later might reveal a long time 
troponin dynamic, indicating that the patient did in fact have an AMI. 
Aims 
The aim is to get an overview on the medical history of the patients that are sent home from the 
ED with a stable troponin elevation. The aim is also to investigate whether there is a long time 
troponin dynamic that we are missing at the ED. 
Methods 
Patients were enrolled from the emergency departments at Sahlgrenska University Hospital in 
Gothenburg. In total, 32 patients were included. Follow up samples of hs-cTnT were collected 
and a review of the patients’ medical records was done. A percental change in hs-cTnT more 
than +60% or -50% was considered pathological. 
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Results 
The average age of these patients was 79 years. A percentage of 56.7% had a known ischemic 
cardiovascular disease, 28.1% had heart failure, 32.3% had an arrhythmia and 25.8% had 
chronic obstructive pulmonary disease (COPD). The patients had 2 or more severe diseases in 
78.1% of the cases. The percental change in hs-cTnT in most of the patients were normal. Five 
patients had a pathological change, but they had other explanations for the acute troponin 
elevation at the ED, such as atrial flutter. 
Conclusions 
The results show that these patients are old and suffer from several co-morbidities. No long 
time troponin dynamic indicating a missed AMI was found. Even though this is a small study 
with few patients, it can still give the ED doctors a small insurance that they’re not missing 
myocardial infarctions at the ED with their current diagnostic routines. 
Key words 
Myocardial infarction, troponin T, stable troponin T elevation, troponin T change, aged 
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1. Introduction 
When a patient presents with symptoms of acute coronary syndrome (ACS) and has an 
inconclusive electrocardiogram (ECG), the diagnosis of myocardial infarction (MI) is often 
based on the short time dynamic of high sensitive cardiac troponin T (hs-cTnT) (1). In the event 
of an acute MI the troponin level usually rises a few hours after myocyte necrosis and reaches 
a plateau after 10-15 hours, after which it slowly starts to decrease (2). Therefore, a significant 
short time rise and/or fall in hs-cTnT levels indicate that the patient is having an MI (1). 
However, if a patient was to attend the ED a few days after the infarction occurred, which 
several reports indicate happens quite often (3, 4), a significant short time dynamic may be 
absent. If a late presenting patient would also have an inconclusive ECG, the diagnosis of MI 
might be incorrectly dismissed, indicating a possibility to miss an MI if it’s based solely on the 
short time dynamics of hs-cTnT. 
This hypothesis is supported by a previous study which showed that in a clinical setting where 
a large hs-cTnT short time dynamic was not mandatory for the diagnosis, small change in hs-
cTnT was common amongst non ST-elevation myocardial infarction (NSTEMI) patients (5). 
The long-term mortality rate in this group was at least as high as it was for patients with large 
short-term changes in hs-cTnT (5).There is also several other reports showing that several MI 
patients have relatively stable troponin elevations during the initial evaluation period (5-12). 
For that reason, the aim of this trial is to evaluate the group of patients that has a stable elevation 
of hs-cTnT at the ED and are sent home, and investigate whether they have a long time troponin 
dynamic that we are missing at the ED, which would consequently suggest that we may be 
missing myocardial infarctions in these cases. 
1.1. Acute myocardial infarction 
Acute myocardial infarction (AMI) is a worldwide cause of great suffering and premature death. 
It is a common presentation of coronary artery disease (1). In 2010, ischemic heart disease 
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caused over 7 million deaths all over the world and was thus the biggest cause of death globally 
(13) and the global disability adjusted life years (DALY) for ischemic heart disease was 1884 
(95% uncertainty interval: 1730-2004) per 100 000 inhabitant (14). 
1.1.1. Statistics 
Swedish statistics 
M. Rosén et al studied the National AMI register in Sweden and found that between 1987 and 
1995, 360 905 cases of AMI were diagnosed amongst 303 324 individuals. The men were 61% 
and 39% were women, and the attack rate was higher amongst men. The difference in attack 
rate between genders was bigger below the age of 60. They also saw a decrease in age-
standardized AMI attack rate and mortality between 1987 and 1995. M. Rosén et al mention 
that lower smoking rates, better secondary prevention such as medication against high blood 
pressure and high cholesterol levels, more aggressive treatment against angina and bigger 
efforts to make lifestyle changes may all be contributing factors to this decrease. (15) 
International statistics 
The WHO MONICA project, a 10 year epidemiological study including 38 populations in 21 
countries all over the world, studied coronary heart disease morbidity and mortality in men and 
women between the ages of 35 to 64 years. They found that the age-standardized annual event 
rates could show large variation from country to country. Tunstall-Pedoe H. et al mention that 
a possible explanation might be many missed events in countries with low event rates. (16) 
1.1.2. Clinical features 
Myocardial ischemia can have many different clinical presentations. In some cases, for example 
in some older patients, women, diabetics, or post-operative and critically ill patients, no 
symptoms are present at all. But typically, it presents with ischemic symptoms occurring during 
exercise or rest. Symptoms include diffuse pain or discomfort that is not affected by movement 
of the affected region. The pain/discomfort can be located to various regions, such as the chest, 
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the arms and the mandibular or epigastric region. Other symptoms are dyspnea and fatigue, and 
also non-specific symptoms such as sweating, nausea or syncope. (1) 
In the article “The value of symptoms and signs in the emergent diagnosis of acute coronary 
syndromes” the authors investigated which specific symptoms that are more likely to be 
associated with AMI, which can be helpful in the diagnostic procedure. Their results indicate 
that central chest pain is more likely to be caused by an AMI in comparison to left-sided chest 
pain and that radiation to both arms has a stronger predictive value than radiation to the right 
arm, which in its turn has a stronger predictive value than radiation to the left arm. They also 
found that sweating was a significant predictive factor, even stronger when observed by the 
doctor than when self-reported by the patient. (17) 
1.1.3. Classification of myocardial infarction 
There are different types of myocardial infarctions. 
Type 1: Spontaneous myocardial infarction 
Rupture, fissuring, erosion or dissection of an atherosclerotic plaque in one or more of the 
coronary arteries leads to an intraluminal thrombus. This results in decreased circulation in the 
myocardial tissue distal to the thrombus which causes necrosis of myocytes in this region. (1) 
This episode may be a consequence of an underlying coronary artery disease, but in some cases 
no signs of this disease is found when a coronary angiography is performed, particularly in 
women. (18-20) 
Type 2: Myocardial infarction secondary to imbalance in oxygen supply and demand 
This type of myocardial infarction is not caused by a plaque-rupture in the coronary arteries. 
Instead it develops secondary to ischemia caused by either a decrease in blood flow to the 
myocardial tissue or by an increase in the myocardial demand of oxygen. (1) 
A type 2 myocardial infarction can be caused by increased levels of catecholamine in the blood 
stream as a result of for example critical illness or undergoing of major (non-cardiac) surgery. 
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(1) Other examples of underlying causes is spasm of the coronary arteries or dysfunction of the 
endothelium. (21-23) Further conditions that can cause this type of infarction is anemia, 
tachyarrhythmia and respiratory failure. (24) 
Type 3: Cardiac death due to myocardial infarction 
When a patient suffers a sudden cardiac death that is believed to be caused by a myocardial 
infarction, it is called a type 3 infarction. Symptoms of acute myocardial infarction in 
combination with new changes on the electrocardiogram indicating a myocardial infarction 
often precede the event of death. In these cases biomarkers may perhaps not be obtained. Either 
the patient dies before his or her level of cardiac biomarkers elevate in the blood stream, or he 
or she dies before a blood sample is even taken. (1) 
Type 4 and 5: Myocardial infarction related to procedures of revascularization 
In some cases, it is necessary to perform a mechanical revascularization procedure: 
percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG). (1) As a 
consequence to these procedures, various events can occur that may cause necrosis of 
myocardial tissue, consequently leading to elevated cardiac troponin levels. (25-28) However, 
its effect on the patient prognosis is not well known if it is an asymptomatic event. (29-31) 
If the infarction is caused by a thrombosis on the stent that was put in, or by restenosis, they 
fall under a particular subcategory (type 4b). (1) 
1.1.4. Electrocardiogram 
The ECG is an important part in the diagnostic procedure of suspected acute myocardial 
infarction. It is recommended to be done and interpreted as soon as possible after onset of 
symptoms. If the first ECG is non-diagnostic and symptoms are still present, it is recommended 
to acquire a new ECG. (1) 
The part of the ECG that is the most interesting in AMI diagnostics is the ST-segment and the 
T-waves. The J-point is used as a reference to value these. The presence of a new ST-elevation 
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≥ 0.1 mV in two contiguous leads is considered pathological in all leads except V2 and V3, 
where the change must be ≥ 0.2 mV in men ≥40 years, ≥0.25 in men <40 years and ≥ 0.15 mV 
in women. Reciprocal ST-segment depression is not unusual in these cases. If there is an ST-
depression ≥ 0.05 mV in two contiguous leads and/or inversion of T-waves in two contiguous 
leads with a prominent R-wave, it is considered pathological and may be caused by an acute 
mycordial infarction. (1) 
Table 1. Criteria for ST-T wave changes in ECG for the diagnosis of acute myocardial 
infarction. (1) 
 
1.1.5. Biomarkers 
At the event of myocardial injury, necrosis of myocytes occurs. This leads to leakage of 
biomarkers that are almost exclusively present in the cardiac tissue. Therefore, these biomarkers 
are checked for example in the emergency department in the diagnostic procedure of acute 
myocardial infarction. (1) 
Troponin is the most preferred biomarker due to its high specificity to myocardial tissue and 
high clinical sensitivity. There are two types of Troponin: Troponin T (TnT) and troponin I. (1) 
There are no reports that show that cardiac troponin I is expressed outside cardiac tissue. 
However, regarding TnT, fetal isoforms exist in skeletal muscle. These isoforms were detected 
with the older assays but the new generations of assay have antibodies that excludes these 
isoforms from being detected. Thus, today’s TnT analysis are highly specific for myocardial 
tissue. (32) The newest high sensitive cardiac troponin T (hs-cTnT) assays have a significantly 
ST elevation ST depression and T wave changes 
New ST elevation at the J point in two 
contiguous leads with the cut point: 
≥ 0.1 mV in all leads other than leads V2-V3 
where the following cut points apply: 
     ≥ 0.2 mV in men and ≥ 40 years. 
     ≥ 0.25 mV in men < 40 years, or ≥ 0.15 
     in women. 
New horizontal or down-sloping ST 
depression ≥ 0.05 mV in two contiguous 
leads and/or T inversion ≥ 0.1 mV in two 
contiguous leads with prominent R wave or 
R/S ratio >1. 
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improved analytical performance and has lowered the 99th percentile upper reference limit to 
14 ng/L (33). 
In Sahlgrenska University, where this trial is done, the biomarker used for diagnostics in acute 
myocardial infarction is hs-cTnT. Therefore, the biomarker that will be focused on in the 
following text will be troponin T. 
Troponin T is one out of three protein subunits in the troponin complex of the contractile 
apparatus in the cardiac myocyte. (34) The troponin complex responds to calcium in the cytosol 
and phosphorylation of regulatory proteins and functions as a modulator of the sarcomere’s 
contractile function. (32) 
At the event of damage to the cardiac myocytes, the membrane leaks these proteins out to the 
bloodstream. Leakage of TnT to the bloodstream does not give us any information on the 
underlying mechanism causing the necrosis of myocytes. In order to distinguish which cases of 
TnT elevations that may be caused by an acute myocardial infarction (AMI) it is important to 
separate stable TnT elevations from acute elevations. (1) 
Acute elevations may occur in acute events such as acute myocardial infarction, aortic 
dissection or an arrhythmia, whilst stable elevations are related to chronic conditions such as 
heart failure and renal failure. Therefore, it is of great value in the diagnostic procedure to differ 
these two types of elevations from each other in the emergency department. This can be done 
by using the fact that chronic elevations do not tend to change significantly over a short period 
of time, while acute elevations show a significant rise and/or fall in TnT levels over a short 
period of time. This requires a series of blood samples from the patient in order to discover an 
eventual rise and/or fall in troponin T levels, which would then distinguish the acute elevations 
from the chronic elevations. (1) 
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When suspecting an acute coronary syndrome, it is therefore recommended that blood samples 
are drawn on the first assessment and 3-6 hours after (1). If the timing of the initial symptoms 
are unclear, further samples may be required (1). At the event of an AMI, the levels of TnT start 
to increase a few hours after myocyte necrosis and reaches a plateau level after 10-15 hours, 
after which it slowly declines (2). Therefore, a change ≥ 20% in a patient with an elevated 
troponin level at baseline is suggested as indicative of an AMI (35). 
Compared to previously used biomarkers for AMI such as CK and CK-MB, TnT levels in serum 
are elevated for a longer time period after onset of symptoms. In cases with late and/or high 
peak concentrations it can be elevated for up to 3 weeks. Therefore TnT is not only an early 
marker for AMI, but also helpful in late diagnosing of AMI in patients who comes to the 
emergency department several days after onset of symptoms. (34) 
The normal variation of the long time changes in troponin T is not yet well defined. Some 
studies have been done but the results vary between different study populations. Vasile VC. et 
al. studied the between-day hs-cTnT change in 20 healthy subjects and found the mean changes 
to be between +103.4% and -87% (36). Frankenstein L. et al. studied the weekly hs-cTnT 
change in 17 healthy individuals and found a variation of +/- 86-87% (37). Bjurman C. et al. 
studied the hs-cTnT level in 94 NSTEMI patients six weeks after the infarction and found that 
most of the patients had >400% in hs-cTnT change (5). Thus, in this study, the interval of long-
term troponin T change considered normal is between +60% and -50%, that is a rise in hs-cTnT 
>60% and a fall in hs-cTnT >50%. 
1.2. Elevation of troponin levels in the absence of acute coronary syndrome 
A troponin T level above the 99th percentile of the upper reference limit (URL) is considered to 
be pathological (1). The new high-sensitivity cardiac troponin assays have lowered the upper 
reference limit to 14 ng/l (38, 39). Consequently the number of patients with elevated troponin 
T has naturally increased (9, 40), particularly amongst patients >65 years in the emergency 
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department without myocardial infarction (41, 42). Therefore, it is of great importance to 
evaluate whether it is an acute or a chronic elevation, since, as mentioned earlier, there are 
different causes to these elevations respectively (32). 
A stable elevation can be caused by a variety of diseases, such as renal failure, severe left 
ventricular hypertrophy and chronic heart failure. Table 2 below is from the article 
“Recommendations for the use of cardiac troponin measurement in acute cardiac care” by 
Thygesen K et al. It shows a list of other reasons for troponin elevation than acute myocardial 
infarction. (32) 
Table 2. Cardiac troponin level elevations not related to acute coronary syndrome. 
Damage related to secondary 
myocardial ischaemia (MI type 2) 
Damage not related to 
myocardial ischaemia 
Indeterminant or 
multifactorial group 
Tachy- or bradyarrhythmias Cardiac contusion 
Apical ballooning 
syndrome 
Aortic dissection and severe aortic valve 
disease 
Cardiac incisions with 
surgery 
Severe pulmonary 
embolism or pulmonary 
hypertension 
Hypo- or hypertension, e.g. 
haemorrhagic shock, hypertensive 
emergency 
Radiofrequency or 
cryoablation therapy 
Peripartum 
cardiomyopathy 
Acute and chronic heart failure without 
significant concomitant coronary artery 
disease (CAD) 
Rhabdomyolysis with 
cardiac involvement Renal failure 
Hypertrophic cardiomyopathy Myocarditis 
Severe acute 
neurological diseases, 
e.g. stroke, trauma 
Coronary vasculitis, e.g. systemic lupus 
erythematosus, Kawasaki syndrome 
Cardiotoxic agents, e.g. 
anthracyclines, herceptin, 
carbon monoxide 
poisoning 
Infiltrative diseases, e.g. 
amyloidosis, sarcoidosis 
Coronary endothelial dysfunction 
without significant CAD, e.g. cocaine 
abuse 
Severe burns affecting 
>30% of body surface Extreme exertion 
    Sepsis 
    Acute respiratory failure 
    
Frequent defibrillator 
shocks 
 
As the table shows, other causes of troponin elevation than AMI can be separated into three 
groups: Secondary myocardial ischemia, diseases not associated with myocardial ischemia and 
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conditions with uncertain or multifactorial mechanisms. They all cause myocardial damage but 
with different or unknown mechanisms. (32) 
Studies have shown that the mortality amongst several of these group of patients is higher if the 
patient has an elevated troponin level. (32) A few studies are presented below that show the 
relation between elevated troponin levels and higher mortality rates in cases without acute 
myocardial infarction. 
For instance, elevation of high sensitive troponin T in patients with chronic heart failure has 
shown a significantly higher risk of death. If combined with elevation of N-terminal pro-B type 
natriuretic peptide (NT-proBNP), it showed a further increase in risk of death. (43) 
Khan NA. et al did a meta-analysis study on the association between troponin T and mortality 
in patients with end-stage renal disease who did not have suspected acute coronary syndrome. 
They found that an elevated troponin T amongst these patients was related to increased 
mortality and increased cardiac death. (44) 
Another meta-analysis study investigated whether elevation of troponin level amongst patients 
with pulmonary embolism is related to higher risk of negative outcome. They showed that an 
elevated troponin level was associated with a higher short-term mortality and adverse outcome 
events. (45) 
Blich M. et al studied hospitalized patients to see if there is a relation between troponin levels 
and negative outcome in hospitalized patients. They found that an increase of troponin levels is 
frequent among consecutive hospitalized patients in absence of an acute coronary syndrome 
and is related to poor short- and long-term outcomes. (46) 
A study that was done to investigate the relation between chronic obstructive pulmonary disease 
(COPD) and high-sensitive cardiac troponin T levels found that a stable COPD was associated 
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with higher troponin levels in comparison to the general population. They also saw that patients 
with a greater severity of the disease had higher levels of troponin. (47) 
The relation between troponin levels and sepsis, septic shock and systemic inflammatory 
response syndrome (SIRS) was investigated by Ammann P. et al. The patients included had no 
acute coronary syndromes. They saw that there was an elevation of troponin in 85% of the 
patients with sepsis, septic shock or SIRS (n=20) whilst none of the patients in the control group 
had an elevation of troponin. (48) 
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2. Aim 
The aim is to get an overview on the medical history of the patients that are sent home from the 
ED with a stable troponin elevation. The aim is also to investigate whether there is a long time 
troponin dynamic that we are missing at the ED. 
2.1. Specific objectives 
How does the medical history look like in the group of patients that attend the ED with the chief 
complaint chest pain and/or dyspnea, and is sent home from the medical section of the ED with 
a stable troponin T elevation? 
How many of the patients that attend the ED with the chief complaint chest pain and/or dyspnea, 
and are sent home from the medical section of the ED with a stable troponin T elevation have 
a long time dynamic change of troponin T? 
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3. Material and Methods 
This trial was conducted at Sahlgrenska University Hospital in Gothenburg, Sweden and 
included patients from the medical section of the emergency departments in Sahlgrenska 
hospital, Mölndal hospital and Östra hospital. 
3.1 Study group 
Patients included in the study were patients who had attended the emergency department (ED) 
with the chief complaints chest pain and/or dyspnea, had at least one high sensitive cardiac 
troponin T (hs-cTnT) value over 14 ng/L and was sent home. 
3.1.1. Enrolling patients 
In the EDs in Gothenburg, attending patients are registered in a program called ELVIS. This 
program was used for collecting patients. Patients who had attended the medical section of the 
ED between 25th of April 2016 and 7th of June 2016 with the chief complaint chest pain or 
dyspnea, and were sent home, were enrolled, since these are two symptoms strongly related to 
myocardial infarction (1). 
The total amount of attendances with the mentioned chief complaints that resulted in the patient 
being sent home was 1372. Note that this is not the same as the amount of attending patients 
since some patients attended the ED more than one time during this time period. The patients 
included were the ones who during their ED visit had at least one hs-cTnT value >14 ng/L, 
which is the upper reference limit at Sahlgrenska University Hospital (38, 39). This landed in a 
total amount of 34 patients. When contacting the patients, two of them said they wanted to be 
excluded from the study. Therefore, the final number of patients was 32.  
The patients’ phone numbers were searched for in Melior, the system used at Sahlgrenska for 
medical records. The numbers that could not be found in Melior were attempted to be found at 
the webpages hitta.se and eniro.se. Then, all the patients whose numbers were managed to be 
found, were contacted. They got information on why they were contacted and were offered to 
book an appointment on which the patient would meet with Dr. Ola Hammarsten or medical 
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student Soza Zangana. Not all patients were reachable, and two of the patients who answered 
the call said they did not want to be included in the study. In total, 23 patients were managed to 
be booked for an appointment. Three of these patients were not able to get to the hospital, which 
is why a home visit was made in these cases. The patients the medical student met were always 
consulted with Dr. Hammarsten. During the consultations, an anamnesis was obtained based 
on a questionnaire that was made, see appendix 1. 
The patients who were not reached by phone, a blood sample was managed to get a hold of in 
other ways. This was done by monitoring Flex-lab to see if recent samples had been taken on 
the patients, in which cases additional analysis were ordered on them including hs-cTnT. One 
patient did not want an appointment but agreed on leaving a blood sample at the nearest 
healthcare center. All blood samples were drawn at least 10 days after the patients’ attendance 
to the ED. 
3.1.2. Calculations and review of medical records 
When the follow up samples were taken, the percental change in hs-cTnT was calculated 
according to the following equation: 
ℎ𝑠−𝑐𝑇𝑛𝑇 (𝑓𝑜𝑙𝑙𝑜𝑤 𝑢𝑝)−ℎ𝑠−𝑐𝑇𝑛𝑇 (𝐸𝐷)
ℎ𝑠−𝑐𝑇𝑛𝑇 (𝐸𝐷)
. If the patient had more 
than one value >14 ng/L from the ED visit, a mean value was calculated and used in the 
equation.  The patients who had booked an appointment with us were informed with the results 
by phone. The patients admitted to the hospital were not available on their phone and were thus 
not contacted. 
A review of all the included patients’ medical records in Melior was also done, so even though 
an appointment was not made with all the patients, information on their medical history was 
still collected. One exception was a patient who had his previous medical records in Halmstad, 
which is why this patient’s medical record was not accessible. 
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3.2. Statistical analysis 
Some of the data collected was statistically analyzed in Microsoft Excel 2016 by using t-test. P 
values <0.05 were considered significant. 
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4. Ethics 
The integrity of the patients was exposed due to the full access of their medical journal and 
blood sample analysis. This ethical issue was taken into consideration as follows. Patients who 
attended for a follow up appointment were given thorough time to read the detailed information 
and fully comprehend the study before signing an informed consent form. Envelopes with 
information regarding the study along with a form for informed consent were sent home to the 
patients who did not attend to a follow up appointment. Even though none of the participants 
that received the form by post replied, the study had still received ethical permissions, according 
to the world medical association declaration of Helsinki:  
1. Biobank med koppling till SWEDEHEART Dnr 803-12. Approved 2012-12-05. 
2. Hur påverkas blodprovsanalyser av olika akuta sjukdomstillstånd? Dnr 755-09. 
Approved 2010-02-11. 
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5. Results 
The total number of patients was 34. When contacting the patients, two of them said they 
wanted to be excluded from the study. Therefore, the final number of patients was 32. Since 
some information was not possible to obtain for some of the patients, the total number of 
patients is not 32 for all the presented variables.  
5.1. Characteristics of the patients. 
Table 3. Baseline characteristics of the patients. 
Variable Value Total number of patients for 
which the value was known 
Average age (years) 78.7 32 
Women 53.1% 32 
Smoking* 58.3% 24 
Average body mass index (BMI)** 25.1 21 
Ischemic cardiovascular disease 56.7% 31 
Heart failure 28.1% 32 
Arrythmia 32.3%  31 
Chronic obstructive pulmonary disease 25.8%  31 
Two or more severe diseases 78.1% 32 
Antihypertensive drugs*** 64.5% 31 
Lipid-lowering drugs 35.5% 31 
Average creatinine level (µmol/L) 95.9 32 
Average troponine T level**** (ng/L) 27.9 32 
ST-T abnormalities at ECG 21.9% 32 
hs-cTnT = high sensitive cardiac troponin T. 
* Current or former smoker; self-reported. 
** Based on selfreported weight and length. 
*** Thiazide diuretics, calcium antagonist, ACE-inhibitor, Angiotensine-antagonist. 
**** At follow up sample. 
The ages ranged between 50-95 years. The majority, 71.9% (23 patients), were between 70-89 
years old. There was a significant age difference between men and women (p=0.01) (figure 1). 
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Figure 1. Patient distribution by age and gender. The total number of patients (n) is 32. The 
number written above the bars is the number of patients in each bar. 
Figure 2 below shows how many severe diseases the patients have. Which diseases defined as 
severe were determined at the author’s discretion and are listed in table 4. 
Table 4. A list of diseases considered as severe. 
Diseases 
Chronic obstructive pulmonary disease (COPD) 
Previous stroke/transient ischemic attack (TIA) 
Coronary artery disease 
Aortic aneurysm 
Heart failure 
Takutsobo cardiomyopathy 
Atrial flutter 
Sick sinus syndrome 
Claudication 
Kidney failure 
Myeloma 
Lymphoma 
Prostate cancer 
Breast cancer 
Skin cancer 
Rheumatoid arthritis 
Parkinson’s disease 
Drug- or alcohol addiction 
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Figure 2. The patients distributed in different bars depending on number of severe diseases. 
For instance, the figure shows that 10 patients have 4 or more severe diseases. The total amount 
of patients (n) is 32. The number written above the bars is the number of patients in each bar. 
The total amount of chief complaints is more according to the medical records in comparison 
to ELVIS (figure 3). This is because several chief complaints can be noted in the medical 
records, while in the registering system ELVIS only one symptom can be registered.  
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Figure 3. The chief complaint for men and women according to medical records (green bars) 
and ELVIS (blue bars) respectively. The number written above the bars is the number of 
patients in each bar.  
*Other symptoms such as tachycardia and dizziness. 
There was another possible cause aside from myocardial infarction for the troponin-elevation 
in 68.9% of the patients (22 patients) (figure 4). The alternative causes for these patients are 
listed in table 5. In the remaining cases, no other explanation for troponin-elevation was found. 
 
Figure 4. The chart shows how many patients who had a possible other cause for troponin 
elevation (32). The number written above the bars is the number of patients in each bar. 
Table 5. Other possible causes for troponin elevation in this study group. 
Other causes for troponin elevation 
Heart failure 
Atrial flutter 
Respiratory failure due to chronic obstructive 
pulmonary disease (COPD) 
Kidney failure 
Sick sinus syndrome 
Angina pectoris 
Recent thorax operation (lung lobectomy) 
Amfetamin abuse 
Recent extreme workout 
Sarcoidosis 
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There were pathological ECG-findings in 75.0% (24 patients) of the cases (figure 5) and 21.9% 
(7 patients) had ST-T abnormalities in their ECG (figure 6). 
 
Figure 5. The number of normal and abnormal ECG’s are demonstrated in this figure. The 
number written above the bars is the number of patients in each bar. 
 
Figure 6. The number written above the bars is the number of patients with each finding. 8 
ECG’s were completely normal, the rest had pathological findings. 
*RBBB = Right bundle branch block. **LBBB = Left bundle branch block. 
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An ultrasound cardiography (UCG) had been done in 18 (56.3%) of the cases and 16 (88.9%) 
of them had pathological findings. 
 
Figure 7. This chart shows the number of patients with pathological and normal UCG-findings. 
The patients who had not undergone a UCG-examination are included in the bar marked “No 
UCG”. The number written above the bars is the amount of patients in each bar. 
Figure 8. Frequency of different UCG-findings. Other findings include amongst others atrial 
enlargement and tricuspid insufficiency. The number written above the bars is the number of 
patients in each bar. 
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Patients with relative estimated glomerular filtration rate (eGFR) above and below 60 
ml/min/1.73 m2 were dichotomized in two groups (figure 9). No significant difference was 
found when comparing the two groups’ hs-cTnT levels (follow up sample) (p=0.67). 
 
Figure 9. Patients dichotomized in groups with eGFR beneath and above 60 ml/min/1.73 m2. 
eGFR = estimated glomerular filtration rate. 
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5.2. Troponin T 
Some of the patients had several troponin T values from their attendance at the emergency 
department. In these cases, a mean value was calculated and used in the figures below. 
The correlation between the patients’ troponin levels and estimated glomerular filtration rate 
(eGFR) is presented in figure 10. The r-value is -0.23 and the p-value is 0.21. 
 
Figure 10. Troponin T levels from the follow up-sample scatterplotted against the patients’ 
relative eGFR. hs-cTnT = high sensitive cardiac troponin T. eGFR = estimated glomerular 
filtration rate. 
Percental change was calculated following this formula: 
ℎ𝑠−𝑐𝑇𝑛𝑇 (𝑓𝑜𝑙𝑙𝑜𝑤 𝑢𝑝)−ℎ𝑠−𝑐𝑇𝑛𝑇 (𝐸𝐷)
ℎ𝑠−𝑐𝑇𝑛𝑇 (𝐸𝐷)
. The 
range of change considered normal in this study was between +60% and -50%. The range was 
chosen with a good safety margin, based on what previous studies have shown is a normal long-
term percental hs-cTnT change (36, 37). The percental change in the majority of the patients 
were within this range, but six patients had changes outside these limits (table 6, figure 11). The 
mean value of the change is 14.0% (SD 69.1%; 95% confidence interval: -55.1%, +83.1%). 
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Table 6. Troponin T levels of each patient at the emergency department (ED) and at follow up 
sample. Patients with pathological changes are highlighted.  
Patient hs-cTnT ED 
hs-cTnT 
follow up Percental change 
1 14,1 14,5 2,8% 
2 14,2 26,7 88,0% 
3 14,7 19,1 29,9% 
4 14,8 15 1,4% 
5 14,9 13,8 -7,4% 
6 15,3 11 -28,1% 
7 15,6 18,7 19,9% 
8 15,9 16,2 2,2% 
9 16,5 17,2 4,2% 
10 17 21,7 27,6% 
11 17 11,8 -30,6% 
12 17,5 15,8 -9,7% 
13 17,7 22,9 29,4% 
14 18,2 16,1 -11,5% 
15 20,5 13,8 -32,7% 
16 18,7 23,8 27,3% 
17 21,4 12,9 -39,7% 
18 20,1 11,3 -43,8% 
19 20,1 17,9 -10,9% 
20 21,8 21,4 -1,8% 
21 23,8 35 47,1% 
22 22,1 19,5 -11,8% 
23 23,7 85,2 259,5% 
24 23,8 19,6 -17,6% 
25 24,6 32,8 33,3% 
26 24,7 79,7 222,7% 
27 30,4 16,8 -44,7% 
28 36,3 15,8 -56,5% 
29 38 44,8 17,9% 
30 44,8 5,96 -86,7% 
31 45,1 61,2 35,7% 
32 101,9 135 32,5% 
hs-cTnT = high sensitive cardiac troponin T. ED = Emergency department. 
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Figure 11. Troponin T levels at the emergency department (ED) and at the follow up sample 
are presented here with a line drawn between every patient’s both samples. 
hs-cTnT = high sensitive cardiac troponin T.  
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6. Discussion 
This study had two aims: To get an overview on the group of patients that are sent home from 
the emergency department (ED) with a stable troponin elevation and to investigate whether 
there is a significant long time troponin dynamic that we are missing in the ED, which would 
consequently suggest that we may be missing myocardial infarctions in these cases. The 
obtained results show that these patients are old and suffer from several co-morbidities. No 
long-time troponin dynamic indicating a missed myocardial infarction was found. 
6.1 Discussion of the results 
The majority of the patients, 71.9% (23 patients), were between 70-89 years old (figure 1). This 
was not very surprising considering that older people have a higher burden of disease and thus 
have a greater risk of having a condition leading to a stable troponin elevation. This result is in 
line with the results in a study made by Cardinaels EP. et al which has shown that elderly people 
normally have higher troponin values (38). 
The men were significantly younger than the women in the study group (p=0.01) (figure 1). 
This is consistent with the results shown by Cardinaels EP. et al showing that men in general 
have an elevated troponin value at a younger age than do women (38). 
The co-morbidity of the study group was high (table 3, figure 2, 5-8). All patients but 2 had one 
or more severe diseases (coronary artery disease, previous stroke and more – see results). These 
results indicate that this is a group of patients with a high burden of disease. This is consistent 
with a number of studies which have shown that elevated troponin T levels are associated with 
several severe diseases such as heart failure and COPD (32, 43, 46, 47). 
The chief complaint according to the medical records shows different information compared to 
ELVIS (figure 3). According to the medical records, some of the patients’ chief complaint was 
nor chest pain or dyspnea. For instance, two of the patients had abdominal pain according to 
the medical records, but were registered in ELVIS as having chest pain. A possible explanation 
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could be that the patient was moved from the surgical section of the ED to the medical section 
of the ED to rule out an AMI, and thus was registered as a “chest pain” in ELVIS by the nurse, 
even if chest pain was not the patients’ chief complaint. 
There are two other possible sources of error concerning the chief complaint. First, the nurse 
could have simply typed in the wrong chief complaint in ELVIS. It is common that the patients 
attend with several symptoms, which sometimes can be diffuse, and can thus lead to 
misinterpretations in a stressed situation. Second, older patients with AMI commonly present 
with atypical symptoms (1), and are thus missed when chest pain or dyspnea are mandatory 
chief complaints for inclusion in the study.  
The patients included in our study were in several cases difficult to communicate with, despite 
that we met them in a non-acute situation in comparison to the situation at the ED. Some of 
them had language difficulties, others focused a lot on irrelevant topics during the consultation. 
Both these factors may have contributed to difficulties with taking an anamnesis at the ED, 
which might have resulted in the clinician missing important information. This could possibly 
affect the handling of these types of patients. For instance, it may cause the clinician to miss 
information indicating an AMI and send the patient home incorrectly, or, in the opposite 
situation, it may lead to the patient being admitted to the hospital because of the uncertain 
anamnesis.  
In our study group, 68.8% (22 patients) had another possible cause for troponin elevation (figure 
4). The fact that there are numerous reasons for troponin elevation presents a challenging and 
possibly deceiving situation for the clinician. If a patient with another possible cause for 
elevated troponin attends the ED with symptoms of AMI, there is a risk that the clinician might 
incorrectly blame the elevated troponin on that other cause. In this group of patients, the 
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clinicians appear to have made a correct medical decision excluding an AMI, considering no 
patients had a missed AMI according to our results. 
In figure 10, the patients estimated glomerular filtration rate (eGFR) was scatter plotted against 
their high sensitive cardiac troponin T (hs-cTnT) levels (follow up sample). No significant 
correlation between eGFR and hs-cTnT levels was found (p=0.21). There was also no 
significant difference in hs-cTnT levels (follow up sample) between patients with eGFR above 
and below 60 ml/min/1.73 m2 (p=0.67). These findings are not consistent with previous findings 
indicating that patients with kidney dysfunction have an elevated troponin T level (49). 
Although, the number of patients in this study were few and not many of them had a severe 
kidney disease. This makes it difficult to draw conclusions regarding the relation between 
troponin T and kidney function from this data. 
In this study, the range of hs-cTnT change considered normal was between +60% and -50%, 
that is a rise in hs-cTnT >60% and a fall in hs-cTnT >50%. The time between the patients’ 
attendance to the ED and their follow up-sample was at least 10 days in order to study their 
long-time troponin-change. The mean value of the percental change in our patients was +14.0% 
(SD 69.1; 95% CI: -55.1%, +83.1%). The confidence interval for the long-time troponin 
dynamic in our study group is similar to that of the random population (36, 37).  
The percental change in most of the patients was within the range considered as normal in this 
study, but five patients had a percental change outside these limits (figure 11, table 6). Three 
patients had a rise in hs-cTnT >60% and 2 patients had a fall in hs-cTnT >50%. 
Patient #2 (table 6) had a percental change of +88%, which was probably due to the fact that 
she had a lung lobectomy done the time between the two samples were taken. Patient #23 and 
#26 (table 6) had an increased troponin value at the follow up sample with +260% and +223% 
respectively. Since these patients were not met with, there is no information on what could be 
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the cause of the elevation. Possible explanations are that they had an AMI after the ED visit, or 
that they were afflicted with another illness affecting their troponin levels. Either case, the 
elevation was probably not due to an AMI at the ED because in that case, troponin should have 
been decreased and not increased at follow up (2). But this doesn’t eliminate the possibility that 
the patients had an AMI at the ED. There might have been a significant long-term decrease in 
these patients’ troponin levels between the ED visit and the follow up sample, which is now 
disguised by a new elevation. 
Patient #28 (table 6) had a percental change of -57%. This could be interpreted as a missed 
AMI, but according to the medical records, the patient had an atrial flutter at the ED, which was 
probably the cause of the troponin elevation at that time. Patient #30 (table 6) had a percental 
change of -87%. This patient was actually diagnosed with an AMI at the ED, since the patient 
had a significant short time-dynamic at the ED with a first hs-cTnT at 8 ng/L and second one 
at 40.5 ng/L. In this case, the patient chose to leave the ED against doctor’s recommendations. 
The reason for leaving was that the patient was unsatisfied with the doctors’ decision of not 
doing an acute PCI. 
In future studies, it would be good to have a larger study group. It would also be interesting to 
study the following additional variables: the time elapsed between the onset of symptom to the 
first sample, how many troponin samples that were taken at the ED, at what time the samples 
were taken and how much time elapsed between the samples at the ED. The recommended time 
between samples are 3-6 hours (1) so it would be interesting to see if these recommendations 
were followed. 
Considering that the interval for normal long-term troponin change is not yet well defined, 
bigger studies need to be done on healthy individuals’ long-term troponin change. 
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6.2. Limitations 
The study population was considerably small. Acute myocardial infarction is a relatively 
common illness which is why a bigger study population is needed for the results to be applicable 
to the general population. The problem in doing a similar but bigger study is that the method 
used in this study is time-consuming. It took a lot of time and a great amount of patience when 
trying to get a hold of all the patients to book an appointment. On top of that, each appointment 
took nearly 30 minutes and some patients even had to be visited at home. And after all 
consultations, the patients were contacted with the results by phone, which also took a lot of 
time since they did not always answer on the first call. To make a bigger study of this kind will 
probably demand a lot of resources. 
It would be practical to send the patients a blood sample form with information and ask them 
to go to the nearest lab and leave a blood sample. The problem is that it would probably concern 
the patients if they are asked to take a blood sample. They might for example misinterpret the 
information and incorrectly believe that they have had a heart attack. Without a physical 
consultation, one can’t take care of that concern or obviate eventual misunderstandings, which 
would be unethical. Possibly it could be solved by having phone contact with the patients both 
before and after taking the follow up sample. And of course, if making a similar study with a 
bigger study group, a strict plan must be in place on how to handle the situation if a missed 
myocardial infarction is found.  
In this trial, there was no control group. This is due to the fact that a lot of people attend the 
emergency department with the symptoms chest pain and dyspnea without a troponin value 
above 14 ng/L. It would not be possible to meet with all these patients in the time frame of this 
study. Possibly this could be done in a future study. 
Not all patients attended a physical follow up. Due to this, all the questions in the questionnaire 
was not answered for all patients, which lessens the strength of the results in some of the data 
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from the questionnaire. The questionnaire was mainly self-reported, which also decreases the 
strength of the results. Although, the self-reported information cannot be obtained in another 
way than from the patient. 
Some of the patients were admitted to the hospital at the time of follow up. Therefore, they 
were unavailable for a follow up appointment, but a follow up-troponin level could still be 
obtained by ordering additional analysis to the samples that were drawn in the hospital. The 
cause of their admittance was not investigated since it was not part of the original aim, and is 
therefore unknown. It is possible that these patients had an illness that affected their hs-cTnT 
levels at the time for the follow up sample. Another bias regarding the follow up sample is that 
the time between the ED sample and the follow up sample is not the same for all patients. The 
only demand was that the follow up sample was taken at least 10 days after the ED visit. It 
would have been preferable to also have an upper limit on the number of days to the follow up 
sample. In our study, the time elapsed between the ED visit and the follow up sample varied a 
lot between the patients and could be up to 1,5 month. 
As noted earlier in the discussion, the chief complaint of the patient was not always chest pain 
or dyspnea despite that ELVIS had registered it as one of these two symptoms. Consequently, 
the chief complaint as noted in ELVIS may not always be correct. Reproducing this study in 
the future should thus base the chief complaint on the information in the medical records rather 
than that in ELVIS.  
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7. Conclusions and implications 
The results show that patients who attend the emergency department (ED) with chest pain 
and/or dyspnea, stable troponin elevations and are sent home are old and suffer from several 
co-morbidities. No long-time troponin dynamic indicating a missed acute myocardial infarction 
(AMI) was found in these patients. Even though this is a small study with few patients, it can 
still give the doctors at the ED a slight indication that they probably do not miss AMI’s at the 
ED with their current diagnostic routines. Further studies with a bigger number of patients are 
needed to verify the results. 
If further studies show opposite results compared to our study, that is, that we miss long time 
troponin changes, the situation of this patient group can be improved. The patient could be 
given the same treatment as patients with acute coronary syndrome, with the risk and benefit of 
the medication concordant with concomitant diseases taken into consideration.   
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8. Populärvetenskaplig sammanfattning på svenska 
Långtidsdynamik i hjärtinfarktsmarkören Troponin T som tecken på genomgången 
hjärtinfarkt – missas hjärtinfarkter på akuten? 
Hjärtinfarkt är en sjukdom som orsaker mycket lidande och är även en vanlig dödsorsak 
internationellt sett. Att fastställa diagnosen hjärtinfarkt är inte alltid så lätt. Diagnosen baseras 
dels på patientens symptom, dels på en undersökning av hjärtats elektriska aktivitet med ett 
elektrokardiogram (EKG) samt blodprov. Om EKG:t är diffust blir blodprovet ibland 
avgörande för diagnostiken. Blodprovet man tar heter troponin T. Detta är ett protein som läcker 
ut i blodbanan vid hjärtskada. Detta värde kan vara stabilt förhöjt hos en del individer med 
andra sjukdomar såsom hjärtsvikt eller kronisk obstruktiv lungsjukdom (KOL). För att 
diagnosen hjärtinfarkt ska ställas behöver man ha en signifikant dynamik i sitt troponinvärde, 
det vill säga troponinvärdet ska öka och/eller sjunka med ett visst antal procent under 
akutbesöket. Om en signifikant troponindynamik inte föreligger talar det emot diagnosen 
hjärtinfarkt, även om värdet är förhöjt. 
I denna studie har man tittat på en grupp på 32 patienter som har en stabil troponinökning. Man 
har utvärderat vad det är för typ av patienter med avseende på till exempel ålder och 
samsjuklighet. Man har också tagit ett uppföljande troponinprov minst 10 dagar efter 
akutbesöket för att se om patienten har en signifikant långtidsdynamik, det vill säga att provet 
förändras mer än ett visst antal procent, vilket då skulle kunna tala för att patientens 
troponinökning på akuten var akut förhöjt och att man då felaktigt avfärdat diagnosen 
hjärtinfarkt. 
Resultaten visade att detta är en patientgrupp som har hög ålder och stor sjukdomsbörda. Många 
hade sedan tidigare antingen en eller flera av sjukdomarna hjärtsvikt, KOL, hjärt- och 
kärlsjukdom med mera. Uppföljningen av troponinvärdet visade att det i de flesta fallen inte 
förelåg någon signifikant dynamik. Dock var det en liten del av patienterna som faktiskt hade 
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en signifikant långtidsdynamik, men i alla dessa fall fanns det andra förklaringar till dynamiken, 
som till exempel att patienten hade ett förmaksflimmer på akuten vilket också kan orsaka en 
akut stegring av troponinvärdet. Således fann man inget fall där diagnosen hjärtinfarkt felaktigt 
avfärdats. 
Denna studie kan innebära en liten trygghet för akutläkarna. Den bekräftar att dagens 
diagnostiska rutiner kring hjärtinfarkt är fungerande och leder inte till några missar. Dock 
behandlar detta en relativt liten studiegrupp. Det skulle vara önskvärt att i framtiden göra en 
liknande studie i större omfattning för att styrka resultaten ytterligare. 
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Appendices 
Appendix 1. 
 
Telefon:   Ring upp (datum): 
Namn: _____________________________________________ 
Personnummer: _____________________________________________ 
Vikt: _________________   Längd: _________________
Kroppsform (1-9) 
Tar du några mediciner? Om ja, vilka? 
 
Ja □           Nej □
Har du några tidigare sjukdomar? Ja □           Nej □ 
Om nej, gå vidare till nästa sida. 
Har du eller har du haft hjärtproblem? 
Om ja, ange: 
______________________________ 
Ja □           Nej □ 
Har du genomgått något ingrepp i hjärtat som 
insättning av pacemaker? 
Ja □           Nej □ 
Har du eller har du haft njurproblem som 
njursvikt? 
Ja □           Nej □ 
Har du eller har du haft lungproblem? 
Om ja, ange: 
______________________________ 
Ja □           Nej □ 
Har du någon gång drabbats av stroke eller 
hjärnblödning? 
Ja □           Nej □ 
Har du diabetes? Ja □           Nej □ 
Har du eller behandlas du för högt blodtryck? Ja □           Nej □ 
Har du eller behandlas du för höga blodfetter? Ja □           Nej □ 
46 
 
Får du eller har du fått strålbehandling mot 
bröstet? 
Får du eller har du fått cellgiftsbehandling? 
Har du några andra sjukdomar? Om ja, ange 
vilka. 
Ja □           Nej □ 
Ja □           Nej □ 
Ja □           Nej □ 
 
Har du haft återkommande smärtor/obehag i 
bröstet? 
 
Ja □           Nej □ 
Om nej, hoppa över alla frågor med * efter. 
Hur länge har du haft 
bröstsmärta/obehag?* 
 
_____________________________
Hur ofta får du 
bröstsmärta/obehag?* 
 
_____________________________
Hur länge håller det i när du väl 
får det?* 
 
_____________________________
Får du bröstsmärtan/obehaget då du går i 
uppförsbacke, uppför trappor eller springer?* 
 
Ja □           Nej □ 
Jag anstränger mig aldrig på det sättet □ 
Får du bröstsmärtan/obehaget då du går 
normalt?* 
 
Ja □           Nej □ 
Vad gör du om du får smärtan/obehaget i bröstet medan du går?* 
Stannar upp □    Fortsätter gå som vanligt □    Tar nitroglycerin □ 
Om du stannar upp, vad händer med bröstsmärtan/obehaget?* 
Minskar/slutar helt □    Ingen skillnad □ 
Om det minskar – hur snabbt minskar det?* 
Mindre än tio minuter □    Mer än tio minuter □ 
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Bedömning: Typisk angina □   Oklart om angina □    Ej angina □   
Har du någonsin haft svår smärta över bröstet 
som höll i mer än en halvtimme? 
 
Ja □           Nej □
 
Du är här för att du tidigare sökt på akutmottagningen. Varför sökte du? 
_____________________________________________ 
Hade du något av följande symtom när du sökte: 
Bröstsmärtor Ja □           Nej □ 
Problem med andningen Ja □           Nej □ 
Onormal trötthet Ja □           Nej □
Svettningar Ja □           Nej □ 
Kräkningar Ja □           Nej □ 
Utstrålning i höger arm eller båda armarna Ja □           Nej □ 
Annat 
_____________________________________________ 
Sedan du sökte på akuten fram till idag – har du haft: 
Bröstsmärtor? Ja □           Nej □ 
Problem med andningen? Ja □           Nej □ 
Onormal trötthet? Ja □           Nej 
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Hur mycket alkohol dricker du i veckan? 
_____________________________________________
Röker du? Ja □           Nej □ 
Om ja, hur många cigaretter per dag? 
_______________________ 
Tränar du regelbundet? 
 
 
Ja □           Nej □ 
Om ja, vad tränar du och hur många timmar i veckan? 
_____________________________________________
Har du haft problem med snarkning? Ja □           Nej □ 
Upplever du mycket stress i din vardag Ja □           Nej □
Har någon i din familj eller nära släkt haft 
hjärtinfarkt innan 65 års ålder? 
Ja □           Nej 
 
